Parkinson’s Disease: A Prionopathy?
Abstract
:1. Introduction
2. α-Synuclein and Lewy Pathology
3. The Prion Concept
3.1. First, the Protein Structure
3.2. Second, the Aggregation Pathway
3.3. Third, Cell to Cell Transmission
3.4. Fourth, Point of Origin and Host Invasion
4. Co-Factors Involved in the Misfolding Process
4.1. Gene Mutations
4.2. Post-Translational Modifications
4.3. Lipid Interactions
4.4. Metals Ions, Pesticides, and Molecular Crowding
4.5. Role of Gut Microbiota
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Parkinson, J. An essay on the shaking palsy. 1817. J. Neuropsychiatry Clin. Neurosci. 2002, 14, 223–236. [Google Scholar] [CrossRef]
- DeMaagd, G.; Philip, A. Parkinson’s Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis. Pharm. Ther. 2015, 40, 504–532. [Google Scholar]
- Moustafa, A.A.; Chakravarthy, S.; Phillips, J.R.; Gupta, A.; Keri, S.; Polner, B.; Jahanshahi, M. Motor symptoms in Parkinson’s disease: A unified framework. Neurosci. Biobehav. Rev. 2016, 68, 727–740. [Google Scholar] [CrossRef]
- Rodriguez-Oroz, M.C.; Jahanshahi, M.; Krack, P.; Litvan, I.; Macias, R.; Bezard, E.; Obeso, J.A. Initial clinical manifestations of Parkinson’s disease: Features and pathophysiological mechanisms. Lancet Neurol. 2009, 8, 1128–1139. [Google Scholar] [CrossRef] [Green Version]
- Sian-Hulsmann, J.; Monoranu, C.; Strobel, S.; Riederer, P. Lewy Bodies: A Spectator or Salient Killer? CNS Neurol. Disord. Drug Targets 2015, 14, 947–955. [Google Scholar] [CrossRef]
- Maroteaux, L.; Campanelli, J.T.; Scheller, R.H. Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 1988, 8, 2804–2815. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Nussbaum, R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997, 276, 2045–2047. [Google Scholar] [CrossRef] [Green Version]
- Spillantini, M.G.; Schmidt, M.L.; Lee, M.-Y.; Trjanowski, R.J. Alpha-synuclein in Lewy bodies. Nature 1997, 388, 839–840. [Google Scholar] [CrossRef] [PubMed]
- Lee, J.C.; Lai, B.T.; Kozak, J.J.; Gray, H.B.; Winkler, J.R. Alpha-synuclein tertiary contact dynamics. J. Phys. Chem. B 2007, 111, 2107–2112. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jao, C.C.; Der-Sarkissian, A.; Chen, J.; Langen, R. Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. Proc. Natl. Acad. Sci. USA 2004, 101, 8331–8336. [Google Scholar] [CrossRef] [Green Version]
- Prusiner, S.B. Novel proteinaceous infectious particles cause scrapie. Science 1982, 216, 136–144. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Prusiner, S.B. Molecular biology of prion diseases. Science 1991, 252, 1515–1522. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Burre, J.; Sharma, M.; Sudhof, T.C. Cell Biology and Pathophysiology of alpha-Synuclein. Cold Spring Harb. Perspect. Med. 2018, 8, a024091. [Google Scholar] [CrossRef]
- Caughey, B. Formation of protease-resistant prion protein in cell-free systems. Curr. Issues Mol. Biol. 2000, 2, 95–101. [Google Scholar] [PubMed]
- Kocisko, D.A.; Come, J.H.; Priola, S.A.; Chesebro, B.; Raymond, G.J.; Lansbury, P.T.; Caughey, B. Cell-free formation of protease-resistant prion protein. Nature 1994, 370, 471–474. [Google Scholar] [CrossRef]
- Telling, G.C.; Parchi, P.; DeArmond, S.J.; Cortelli, P.; Montagna, P.; Gabizon, R.; Prusiner, S.B. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 1996, 274, 2079–2082. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Silveira, J.R.; Raymond, G.J.; Hughson, A.G.; Race, R.E.; Sim, V.L.; Hayes, S.F.; Caughey, B. The most infectious prion protein particles. Nature 2005, 437, 257–261. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Acquatella-Tran Van Ba, I.; Imberdis, T.; Perrier, V. From prion diseases to prion-like propagation mechanisms of neurodegenerative diseases. Int. J. Cell Biol. 2013, 2013, 975832. [Google Scholar] [CrossRef] [PubMed]
- Renner, M.; Melki, R. Protein aggregation and prionopathies. Pathol. Biol. 2014, 62, 162–168. [Google Scholar] [CrossRef]
- Dunning, C.J.; George, S.; Brundin, P. What′s to like about the prion-like hypothesis for the spreading of aggregated alpha-synuclein in Parkinson disease? Prion 2013, 7, 92–97. [Google Scholar] [CrossRef] [Green Version]
- Masuda-Suzukake, M.; Nonaka, T.; Hosokawa, M.; Kubo, M.; Shimozawa, A.; Akiyama, H.; Hasegawa, M. Pathological alpha-synuclein propagates through neural networks. Acta Neuropathol. Commun. 2014, 2, 88. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Volpicelli-Daley, L.A.; Luk, K.C.; Patel, T.P.; Tanik, S.A.; Riddle, D.M.; Stieber, A.; Lee, V.M.Y. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011, 72, 57–71. [Google Scholar] [CrossRef] [Green Version]
- Lee, S.J.; Desplats, P.; Sigurdson, C.; Tsigelny, I.; Masliah, E. Cell-to-cell transmission of non-prion protein aggregates. Nat. Rev. Neurol. 2010, 6, 702–706. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fiorini, M.; Iselle, G.; Perra, D.; Bongianni, M.; Capaldi, S.; Sacchetto, L.; Zanusso, G. High Diagnostic Accuracy of RT-QuIC Assay in a Prospective Study of Patients with Suspected sCJD. Int. J. Mol. Sci. 2020, 21, 880. [Google Scholar] [CrossRef] [Green Version]
- Orru, C.D.; Wilham, J.M.; Vascellari, S.; Hughson, A.G.; Caughey, B. New generation QuIC assays for prion seeding activity. Prion 2012, 6, 147–152. [Google Scholar] [CrossRef] [Green Version]
- Vascellari, S.; Orru, C.D.; Hughson, A.G.; King, D.; Barron, R.; Wilham, J.M.; Caughey, B. Prion seeding activities of mouse scrapie strains with divergent PrPSc protease sensitivities and amyloid plaque content using RT-QuIC and eQuIC. PLoS ONE 2012, 7, e48969. [Google Scholar]
- Bongianni, M.; Ladogana, A.; Capaldi, S.; Klotz, S.; Baiardi, S.; Cagnin, A.; Zanusso, G. alpha-Synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies. Ann. Clin. Transl. Neurol. 2019, 6, 2120–2126. [Google Scholar] [CrossRef]
- Fairfoul, G.; McGuire, L.I.; Pal, S.; Ironside, J.W.; Neumann, J.; Christie, S.; Green, A.J. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann. Clin. Transl. Neurol. 2016, 3, 812–818. [Google Scholar] [CrossRef] [PubMed]
- Groveman, B.R.; Orrù, C.D.; Hughson, A.G.; Raymond, L.D.; Zanusso, G.; Ghetti, B.; Caughey, B. Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC. Acta Neuropathol. Commun. 2018, 6, 7. [Google Scholar] [CrossRef] [PubMed]
- Kordower, J.H.; Chu, Y.; Hauser, R.A.; Freeman, T.B.; Olanow, C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat. Med. 2008, 14, 504–506. [Google Scholar] [CrossRef]
- Li, J.Y.; Englund, E.; Holton, J.L.; Soulet, D.; Hagell, P.; Lees, A.J.; Brundin, P. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat. Med. 2008, 14, 501–503. [Google Scholar] [CrossRef]
- Freundt, E.C.; Maynard, N.; Clancy, E.K.; Roy, S.; Bousset, L.; Sourigues, Y.; Brahic, M. Neuron-to-neuron transmission of alpha-synuclein fibrils through axonal transport. Ann. Neurol. 2012, 72, 517–524. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hansen, C.; Angot, E.; Bergström, A.L.; Steiner, J.A.; Pieri, L.; Paul, G.; Brundin, P. alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Investig. 2011, 121, 715–725. [Google Scholar] [CrossRef] [Green Version]
- Ma, J.; Gao, J.; Wang, J.; Xie, A. Prion-Like Mechanisms in Parkinson’s Disease. Front. Neurosci. 2019, 13, 552. [Google Scholar] [CrossRef] [PubMed]
- Tsigelny, I.F.; Crews, L.; Desplats, P.; Shaked, G.M.; Sharikov, Y.; Mizuno, H.; Masliah, E. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer’s and Parkinson’s diseases. PLoS ONE 2008, 3, e3135. [Google Scholar] [CrossRef]
- Danzer, K.M.; Kranich, L.R.; Ruf, W.P.; Cagsal-Getkin, O.; Winslow, A.R.; Zhu, L.; McLean, P.J. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 2012, 7, 42. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fevrier, B.; Vilette, D.; Archer, F.; Loew, D.; Faigle, W.; Vidal, M.; Raposo, G. Cells release prions in association with exosomes. Proc. Natl. Acad. Sci. USA 2004, 101, 9683–9688. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Guo, J.L.; Lee, V.M. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med. 2014, 20, 130–138. [Google Scholar] [CrossRef] [Green Version]
- Lee, H.J.; Patel, S.; Lee, S.J. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci. 2005, 25, 6016–6024. [Google Scholar] [CrossRef]
- Bousset, L.; Melki, R. Infectious properties of protein aggregates involved in neurodegenerative diseases. Biol. Aujourdhui. 2013, 207, 55–59. [Google Scholar] [CrossRef]
- Bousset, L.; Pieri, L.; Ruiz-Arlandis, G.; Gath, J.; Jensen, P.H.; Habenstein, B.; Melki, R. Structural and functional characterization of two alpha-synuclein strains. Nat. Commun. 2013, 4, 2575. [Google Scholar] [CrossRef] [Green Version]
- Bessen, R.A.; Martinka, S.; Kelly, J.; Gonzalez, D. Role of the lymphoreticular system in prion neuroinvasion from the oral and nasal mucosa. J. Virol. 2009, 83, 6435–6445. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Denkers, N.D.; Seelig, D.M.; Telling, G.C.; Hoover, E.A. Aerosol and nasal transmission of chronic wasting disease in cervidized mice. J. Gen. Virol. 2010, 91 Pt 6, 1651–1658. [Google Scholar] [CrossRef]
- Hamir, A.N.; Kunkle, R.A.; Richt, J.A.; Miller, J.M.; Greenlee, J.J. Experimental transmission of US scrapie agent by nasal, peritoneal, and conjunctival routes to genetically susceptible sheep. Vet. Pathol. 2008, 45, 7–11. [Google Scholar] [CrossRef]
- Mabbott, N.A. How do PrP(Sc) Prions Spread between Host Species, and within Hosts? Pathogens 2017, 6, 60. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Beekes, M.; McBride, P.A. Early accumulation of pathological PrP in the enteric nervous system and gut-associated lymphoid tissue of hamsters orally infected with scrapie. Neurosci. Lett. 2000, 278, 181–184. [Google Scholar] [CrossRef]
- Kujala, P.; Raymond, C.R.; Romeijn, M.; Godsave, S.F.; van Kasteren, S.I.; Wille, H.; Peters, P.J. Prion uptake in the gut: Identification of the first uptake and replication sites. PLoS Pathog 2011, 7, e1002449. [Google Scholar] [CrossRef]
- McBride, P.A.; Schulz-Schaeffer, W.J.; Donaldson, M.; Bruce, M.; Diringer, H.; Kretzschmar, H.A.; Beekes, M. Early spread of scrapie from the gastrointestinal tract to the central nervous system involves autonomic fibers of the splanchnic and vagus nerves. J. Virol. 2001, 75, 9320–9327. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Glatzel, M.; Heppner, F.L.; Albers, K.M.; Aguzzi, A. Sympathetic innervation of lymphoreticular organs is rate limiting for prion neuroinvasion. Neuron 2001, 31, 25–34. [Google Scholar] [CrossRef] [Green Version]
- Shearin, H.; Bessen, R.A. Axonal and transynaptic spread of prions. J. Virol. 2014, 88, 8640–8655. [Google Scholar] [CrossRef] [Green Version]
- Bessen, R.A.; Shearin, H.; Martinka, S.; Boharski, R.; Lowe, D.; Wilham, J.M.; Wiley, J.A. Prion shedding from olfactory neurons into nasal secretions. PLoS Pathog 2010, 6, e1000837. [Google Scholar] [CrossRef] [Green Version]
- Zanusso, G.; Ferrari, S.; Cardone, F.; Zampieri, P.; Gelati, M.; Fiorini, M.; Monaco, S. Detection of pathologic prion protein in the olfactory epithelium in sporadic Creutzfeldt-Jakob disease. N. Engl. J. Med. 2003, 348, 711–719. [Google Scholar] [CrossRef]
- Braak, H.; Del Tredici, K.; Rüb, U.; De Vos, R.A.; Steur EN, J.; Braak, E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 2003, 24, 197–211. [Google Scholar] [CrossRef]
- Braak, H.; del Tredici, K. Potential Pathways of Abnormal Tau and alpha-Synuclein Dissemination in Sporadic Alzheimer’s and Parkinson’s Diseases. Cold Spring Harb. Perspect. Biol. 2016, 8, a023630. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Braak, H.; Rüb, U.; Gai, W.P.; Del Tredici, K. Idiopathic Parkinson’s disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. 2003, 110, 517–536. [Google Scholar] [CrossRef] [PubMed]
- Makin, S. Pathology: The prion principle. Nature 2016, 538, S13–S16. [Google Scholar] [CrossRef]
- Knudsen, K.; Fedorova, T.D.; Hansen, A.K.; Sommerauer, M.; Otto, M.; Svendsen, K.B.; Borghammer, P. In-vivo staging of pathology in REM sleep behaviour disorder: A multimodality imaging case-control study. Lancet Neurol. 2018, 17, 618–628. [Google Scholar] [CrossRef] [Green Version]
- Lohmann, S.; Bernis, M.E.; Tachu, B.J.; Ziemski, A.; Grigoletto, J.; Tamgüney, G. Oral and intravenous transmission of alpha-synuclein fibrils to mice. Acta Neuropathol. 2019, 138, 515–533. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Svensson, E.; Horváth-Puhó, E.; Thomsen, R.W.; Djurhuus, J.C.; Pedersen, L.; Borghammer, P.; Sørensen, H.T. Vagotomy and subsequent risk of Parkinson’s disease. Ann. Neurol. 2015, 78, 522–529. [Google Scholar] [CrossRef]
- Ulusoy, A.; Phillips, R.J.; Helwig, M.; Klinkenberg, M.; Powley, T.L.; Di Monte, D.A. Brain-to-stomach transfer of alpha-synuclein via vagal preganglionic projections. Acta Neuropathol. 2017, 133, 381–393. [Google Scholar] [CrossRef] [Green Version]
- Horsager, J.; Andersen, K.B.; Knudsen, K.; Skjærbæk, C.; Fedorova, T.D.; Okkels, N.; Borghammer, P. Brain-first versus body-first Parkinson’s disease: A multimodal imaging case-control study. Brain 2020, 143, 3077–3088. [Google Scholar] [CrossRef]
- Visanji, N.P.; Brooks, P.L.; Hazrati, L.N.; Lang, A.E. The prion hypothesis in Parkinson’s disease: Braak to the future. Acta Neuropathol. Commun. 2013, 1, 2. [Google Scholar] [CrossRef] [Green Version]
- Fujiwara, H.; Hasegawa, M.; Dohmae, N.; Kawashima, A.; Masliah, E.; Goldberg, M.S.; Iwatsubo, T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4, 160–164. [Google Scholar] [CrossRef] [PubMed]
- Giannopoulos, P.N.; Robertson, C.; Jodoin, J.; Paudel, H.; Booth, S.A.; LeBlanc, A.C. Phosphorylation of prion protein at serine 43 induces prion protein conformational change. J. Neurosci. 2009, 29, 8743–8751. [Google Scholar] [CrossRef]
- Pankratz, N.; Foroud, T. Genetics of Parkinson disease. Genet. Med. 2007, 9, 801–811. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mastrianni, J.A. The genetics of prion diseases. Genet. Med. 2010, 12, 187–195. [Google Scholar] [CrossRef] [Green Version]
- Bernardi, L.; Bruni, A.C. Mutations in Prion Protein Gene: Pathogenic Mechanisms in C-Terminal vs. N-Terminal Domain, a Review. Int. J. Mol. Sci. 2019, 20, 3606. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ferreira, M.; Massano, J. An updated review of Parkinson’s disease genetics and clinicopathological correlations. Acta Neurol. Scand 2017, 135, 273–284. [Google Scholar] [CrossRef] [PubMed]
- Schaffert, L.N.; Carter, W.G. Do Post-Translational Modifications Influence Protein Aggregation in Neurodegenerative Diseases: A Systematic Review. Brain Sci. 2020, 10, 232. [Google Scholar] [CrossRef]
- Zhang, J.; Li, X.; Li, J.D. The Roles of Post-translational Modifications on alpha-Synuclein in the Pathogenesis of Parkinson’s Diseases. Front. Neurosci. 2019, 13, 381. [Google Scholar] [CrossRef] [Green Version]
- Prusiner, S.B. Prions. Proc. Natl. Acad. Sci. USA 1998, 95, 13363–13383. [Google Scholar] [CrossRef] [Green Version]
- Kim, W.S.; Kagedal, K.; Halliday, G.M. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res. Ther. 2014, 6, 73. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hannaoui, S.; Shim, S.Y.; Cheng, Y.C.; Corda, E.; Gilch, S. Cholesterol balance in prion diseases and Alzheimer’s disease. Viruses 2014, 6, 4505–4535. [Google Scholar] [CrossRef] [Green Version]
- Pani, A.; Norfo, C.; Abete, C.; Mulas, C.; Putzolu, M.; Laconi, S.; Dessì, S. Antiprion activity of cholesterol esterification modulators: A comparative study using ex vivo sheep fibroblasts and lymphocytes and mouse neuroblastoma cell lines. Antimicrob. Agents Chemother. 2007, 51, 4141–4147. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Scano, P.; Rosa, A.; Incani, A.; Maestrale, C.; Santucciu, C.; Perra, D.; Ligios, C. (1)H NMR brain metabonomics of scrapie exposed sheep. Mol. Biosyst. 2015, 11, 2008–2016. [Google Scholar] [CrossRef] [Green Version]
- Vascellari, S.; Banni, S.; Vacca, C.; Vetrugno, V.; Cardone, F.; Di Bari, M.A.; Pani, A. Accumulation and aberrant composition of cholesteryl esters in Scrapie-infected N2a cells and C57BL/6 mouse brains. Lipids Health Dis. 2011, 10, 132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mesa-Herrera, F.; Taoro-González, L.; Valdés-Baizabal, C.; Diaz, M.; Marín, R. Lipid and Lipid Raft Alteration in Aging and Neurodegenerative Diseases: A Window for the Development of New Biomarkers. Int. J. Mol. Sci. 2019, 20, 3810. [Google Scholar] [CrossRef] [Green Version]
- Gaeta, A.; Hider, R.C. The crucial role of metal ions in neurodegeneration: The basis for a promising therapeutic strategy. Br. J. Pharmacol. 2005, 146, 1041–1059. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brown, D.R.; Qin, K.; Herms, J.W.; Madlung, A.; Manson, J.; Strome, R.; Kretzschmar, H. The cellular prion protein binds copper in vivo. Nature 1997, 390, 684–687. [Google Scholar] [CrossRef]
- Paik, S.R.; Shin, H.J.; Lee, J.H.; Chang, C.S.; Kim, J. Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem. J. 1999, 340 Pt. 3, 821–828. [Google Scholar] [CrossRef]
- Thakur, A.K.; Srivastava, A.K.; Srinivas, V.; Chary KV, R.; Rao, C.M. Copper alters aggregation behavior of prion protein and induces novel interactions between its N- and C-terminal regions. J. Biol. Chem. 2011, 286, 38533–38545. [Google Scholar] [CrossRef] [Green Version]
- Walter, E.D.; Chattopadhyay, M.; Millhauser, G.L. The affinity of copper binding to the prion protein octarepeat domain: Evidence for negative cooperativity. Biochemistry 2006, 45, 13083–13092. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lemire, J.A.; Harrison, J.J.; Turner, R.J. Antimicrobial activity of metals: Mechanisms, molecular targets and applications. Nat. Rev. Microbiol. 2013, 11, 371–384. [Google Scholar] [CrossRef]
- Wang, X.; Moualla, D.; Wright, J.A.; Brown, D.R. Copper binding regulates intracellular alpha-synuclein localisation, aggregation and toxicity. J. Neurochem. 2010, 113, 704–714. [Google Scholar] [CrossRef]
- Minton, A.P. Implications of macromolecular crowding for protein assembly. Curr. Opin. Struct. Biol. 2000, 10, 34–39. [Google Scholar] [CrossRef]
- Shtilerman, M.D.; Ding, T.T.; Lansbury, P.T. Molecular crowding accelerates fibrillization of alpha-synuclein: Could an increase in the cytoplasmic protein concentration induce Parkinson’s disease? Biochemistry 2002, 41, 3855–3860. [Google Scholar] [CrossRef] [PubMed]
- Uversky, V.N.; Cooper, E.M.; Bower, K.S.; Li, J.; Fink, A.L. Accelerated alpha-synuclein fibrillation in crowded milieu. FEBS Lett. 2002, 515, 99–103. [Google Scholar] [CrossRef] [Green Version]
- Chin-Chan, M.; Navarro-Yepes, J.; Quintanilla-Vega, B. Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front. Cell. Neurosci. 2015, 9, 124. [Google Scholar] [CrossRef] [Green Version]
- Gordon, I.; Abdulla, E.M.; Campbell, I.C.; Whatley, S.A. Phosmet induces up-regulation of surface levels of the cellular prion protein. NeuroReport 1998, 9, 1391–1395. [Google Scholar] [CrossRef]
- Purdey, M. The UK epidemic of BSE: Slow virus or chronic pesticide-initiated modification of the prion protein? Part 2: An epidemiological perspective. Med. Hypotheses 1996, 46, 445–454. [Google Scholar] [CrossRef]
- Lafon, P.A.; Imberdis, T.; Wang, Y.; Torrent, J.; Robitzer, M.; Huetter, E.; Perrier, V. Low doses of bioherbicide favour prion aggregation and propagation in vivo. Sci. Rep. 2018, 8, 8023. [Google Scholar] [CrossRef] [Green Version]
- Tanner, C.M.; Kamel, F.; Ross, G.W.; Hoppin, J.A.; Goldman, S.M.; Korell, M.; Langston, J.W. Rotenone, paraquat, and Parkinson’s disease. Environ. Health Perspect. 2011, 119, 866–872. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Betarbet, R.; Sherer, T.B.; MacKenzie, G.; Garcia-Osuna, M.; Panov, A.V.; Greenamyre, J.T. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat. Neurosci. 2000, 3, 1301–1306. [Google Scholar] [CrossRef]
- Munishkina, L.A.; Cooper, E.M.; Uversky, V.N.; Fink, A.L. The effect of macromolecular crowding on protein aggregation and amyloid fibril formation. J. Mol. Recognit. 2004, 17, 456–464. [Google Scholar] [CrossRef]
- Claus, S.P.; Guillou, H.; Ellero-Simatos, S. The gut microbiota: A major player in the toxicity of environmental pollutants? NPJ Biofilms Microbiomes 2016, 2, 16003. [Google Scholar] [CrossRef] [PubMed]
- Tamburini, E.; Doni, L.; Lussu, R.; Meloni, F.; Cappai, G.; Carucci, A.; Vitali, F. Impacts of Anthropogenic Pollutants on Benthic Prokaryotic Communities in Mediterranean Touristic Ports. Front. Microbiol. 2020, 11, 1234. [Google Scholar] [CrossRef]
- Thursby, E.; Juge, N. Introduction to the human gut microbiota. Biochem. J. 2017, 474, 1823–1836. [Google Scholar] [CrossRef]
- Yang, D.; Zhao, D.; Shah SZ, A.; Wu, W.; Lai, M.; Zhang, X.; Yang, L. Implications of gut microbiota dysbiosis and metabolic changes in prion disease. Neurobiol. Dis. 2020, 135, 104704. [Google Scholar] [CrossRef]
- Rinninella, E.; Raoul, P.; Cintoni, M.; Franceschi, F.; Miggiano GA, D.; Gasbarrini, A.; Mele, M.C. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms 2019, 7, 14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ogbonnaya, E.S.; Clarke, G.; Shanahan, F.; Dinan, T.G.; Cryan, J.F.; O’Leary, O.F. Adult Hippocampal Neurogenesis Is Regulated by the Microbiome. Biol. Psychiatry 2015, 78, e7–e9. [Google Scholar] [CrossRef]
- Baumler, A.J.; Sperandio, V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature 2016, 535, 85–93. [Google Scholar] [CrossRef] [Green Version]
- Gensollen, T.; Iyer, S.S.; Kasper, D.L.; Blumberg, R.S. How colonization by microbiota in early life shapes the immune system. Science 2016, 352, 539–544. [Google Scholar] [CrossRef] [Green Version]
- Dinan, T.G.; Cryan, J.F. The Microbiome-Gut-Brain Axis in Health and Disease. Gastroenterol. Clin. N. Am. 2017, 46, 77–89. [Google Scholar] [CrossRef] [Green Version]
- Mayer, E.A.; Knight, R.; Mazmanian, S.K.; Cryan, J.F.; Tillisch, K. Gut microbes and the brain: Paradigm shift in neuroscience. J. Neurosci. 2014, 34, 15490–15496. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- El Aidy, S.; Dinan, T.G.; Cryan, J.F. Gut Microbiota: The Conductor in the Orchestra of Immune-Neuroendocrine Communication. Clin. Ther. 2015, 37, 954–967. [Google Scholar] [CrossRef]
- Grenham, S.; Clarke, G.; Cryan, J.F.; Dinan, T.G. Brain-gut-microbe communication in health and disease. Front. Physiol. 2011, 2, 94. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rhee, S.H.; Pothoulakis, C.; Mayer, E.A. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat. Rev. Gastroenterol. Hepatol. 2009, 6, 306–314. [Google Scholar] [CrossRef] [Green Version]
- Cersosimo, M.G.; Benarroch, E.E. Pathological correlates of gastrointestinal dysfunction in Parkinson’s disease. Neurobiol. Dis. 2012, 46, 559–564. [Google Scholar] [CrossRef] [PubMed]
- Devos, D.; Lebouvier, T.; Lardeux, B.; Biraud, M.; Rouaud, T.; Pouclet, H.; Derkinderen, P. Colonic inflammation in Parkinson’s disease. Neurobiol. Dis. 2013, 50, 42–48. [Google Scholar] [CrossRef] [PubMed]
- Forsyth, C.B.; Shannon, K.M.; Kordower, J.H.; Voigt, R.M.; Shaikh, M.; Jaglin, J.A.; Keshavarzian, A. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease. PLoS ONE 2011, 6, e28032. [Google Scholar] [CrossRef] [Green Version]
- Savica, R.; Carlin, J.M.; Grossardt, B.R.; Bower, J.H.; Ahlskog, J.E.; Maraganore, D.M.; Rocca, W.A. Medical records documentation of constipation preceding Parkinson disease: A case-control study. Neurology 2009, 73, 1752–1758. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nagatsu, T.; Mogi, M.; Ichinose, H.; Togari, A. Cytokines in Parkinson’s disease. J. Neural. Transm. Suppl. 2000, 143–151. [Google Scholar]
- Sampson, T.R.; Debelius, J.W.; Thron, T.; Janssen, S.; Shastri, G.G.; Ilhan, Z.E.; Mazmanian, S.K. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease. Cell 2016, 167, 1469–1480.e12. [Google Scholar] [CrossRef] [Green Version]
- Bedarf, J.R.; Hildebrand, F.; Coelho, L.P.; Sunagawa, S.; Bahram, M.; Goeser, F.; Wüllner, U. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naive Parkinson’s disease patients. Genome Med. 2017, 9, 39. [Google Scholar] [CrossRef]
- Hasegawa, S.; Goto, S.; Tsuji, H.; Okuno, T.; Asahara, T.; Nomoto, K.; Hirayama, M. Intestinal Dysbiosis and Lowered Serum Lipopolysaccharide-Binding Protein in Parkinson’s Disease. PLoS ONE 2015, 10, e0142164. [Google Scholar] [CrossRef] [Green Version]
- Hill-Burns, E.M.; Debelius, J.W.; Morton, J.T.; Wissemann, W.T.; Lewis, M.R.; Wallen, Z.D.; Payami, H. Parkinson’s disease and Parkinson’s disease medications have distinct signatures of the gut microbiome. Mov. Disord. 2017, 32, 739–749. [Google Scholar] [CrossRef]
- Keshavarzian, A.; Green, S.J.; Engen, P.A.; Voigt, R.M.; Naqib, A.; Forsyth, C.B.; Shannon, K.M. Colonic bacterial composition in Parkinson’s disease. Mov. Disord. 2015, 30, 1351–1360. [Google Scholar] [CrossRef]
- Melis, M.; Vascellari, S.; Santoru, M.L.; Oppo, V.; Fabbri, M.; Sarchioto, M.; Cossu, G. Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel. Eur. J. Neurol. 2021, 28, 1198–1209. [Google Scholar] [CrossRef] [PubMed]
- Scheperjans, F.; Aho, V.; Pereira, P.A.; Koskinen, K.; Paulin, L.; Pekkonen, E.; Auvinen, P. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov. Disord. 2015, 30, 350–358. [Google Scholar] [CrossRef] [PubMed]
- Unger, M.M.; Spiegel, J.; Dillmann, K.U.; Grundmann, D.; Philippeit, H.; Bürmann, J.; Schäfer, K.H. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat. Disord. 2016, 32, 66–72. [Google Scholar] [CrossRef]
- Vascellari, S.; Melis, M.; Cossu, G.; Melis, M.; Serra, A.; Palmas, V.; Barbarossa, I.T. Genetic variants of TAS2R38 bitter taste receptor associate with distinct gut microbiota traits in Parkinson’s disease: A pilot study. Int. J. Biol. Macromol. 2020, 165 Pt A, 665–674. [Google Scholar] [CrossRef]
- Vascellari, S.; Melis, M.; Palmas, V.; Pisanu, S.; Serra, A.; Perra, D.; Manzin, A. Clinical Phenotypes of Parkinson’s Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes. Biomolecules 2021, 11, 144. [Google Scholar] [CrossRef]
- Vascellari, S.; Palmas, V.; Melis, M.; Pisanu, S.; Cusano, R.; Uva, P.; Manzin, A. Gut Microbiota and Metabolome Alterations Associated with Parkinson’s Disease. Msystems 2020, 5, e00561-20. [Google Scholar] [CrossRef]
- Zeng, M.Y.; Inohara, N.; Nunez, G. Mechanisms of inflammation-driven bacterial dysbiosis in the gut. Mucosal. Immunol. 2017, 10, 18–26. [Google Scholar] [CrossRef] [Green Version]
- Kelly, L.P.; Carvey, P.M.; Keshavarzian, A.; Shannon, K.M.; Shaikh, M.; Bakay, R.A.; Kordower, J.H. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson’s disease. Mov. Disord. 2014, 29, 999–1009. [Google Scholar] [CrossRef] [PubMed]
- Lange, J.H.; Niehaus, I.; Thomulka, K.W. Is endotoxin an environmental cause of Parkinson’s disease? Neuroepidemiology 2003, 22, 313. [Google Scholar] [CrossRef] [PubMed]
- Clairembault, T.; Leclair-Visonneau, L.; Coron, E.; Bourreille, A.; Le Dily, S.; Vavasseur, F.; Derkinderen, P. Structural alterations of the intestinal epithelial barrier in Parkinson’s disease. Acta Neuropathol. Commun. 2015, 3, 12. [Google Scholar] [CrossRef] [Green Version]
- Miraglia, F.; Colla, E. Microbiome, Parkinson’s Disease and Molecular Mimicry. Cells 2019, 8, 222. [Google Scholar] [CrossRef] [Green Version]
- Bokranz, W.; Wang, X.; Tschäpe, H.; Römling, U. Expression of cellulose and curli fimbriae by Escherichia coli isolated from the gastrointestinal tract. J. Med. Microbiol. 2005, 54 Pt 12, 1171–1182. [Google Scholar] [CrossRef]
- Phillips, R.J.; Walter, G.C.; Ringer, B.E.; Higgs, K.M.; Powley, T.L. Alpha-synuclein immunopositive aggregates in the myenteric plexus of the aging Fischer 344 rat. Exp. Neurol. 2009, 220, 109–119. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Manfredsson, F.P.; Luk, K.C.; Benskey, M.J.; Gezer, A.; Garcia, J.; Kuhn, N.C.; Kordower, J.H. Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology. Neurobiol. Dis. 2018, 112, 106–118. [Google Scholar] [CrossRef]
- Pasupuleti, M.; Roupe, M.; Rydengård, V.; Surewicz, K.; Surewicz, W.K.; Chalupka, A.; Schmidtchen, A. Antimicrobial activity of human prion protein is mediated by its N-terminal region. PLoS ONE 2009, 4, e7358. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dervishi, E.; Lam, T.H.; Dunn, S.M.; Zwierzchowski, G.; Saleem, F.; Wishart, D.S.; Ametaj, B.N. Recombinant mouse prion protein alone or in combination with lipopolysaccharide alters expression of innate immunity genes in the colon of mice. Prion 2015, 9, 59–73. [Google Scholar] [CrossRef] [PubMed]
- Kretzschmar, H.A.; Prusiner, S.B.; Stowring, L.E.; DeArmond, S.J. Scrapie prion proteins are synthesized in neurons. Am. J. Pathol. 1986, 122, 1–5. [Google Scholar]
- Moser, M.; Colello, R.J.; Pott, U.; Oesch, B. Developmental expression of the prion protein gene in glial cells. Neuron 1995, 14, 509–517. [Google Scholar] [CrossRef] [Green Version]
- Lorente-Picon, M.; Laguna, A. New Avenues for Parkinson’s Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota. Biomolecules 2021, 11, 433. [Google Scholar] [CrossRef]
- De Luigi, A.; Colombo, L.; Diomede, L.; Capobianco, R.; Mangieri, M.; Miccolo, C.; Salmona, M. The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS ONE 2008, 3, e1888. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Varges, D.; Manthey, H.; Heinemann, U.; Ponto, C.; Schmitz, M.; Schulz-Schaeffer, W.J.; Zerr, I. Doxycycline in early CJD: A double-blinded randomised phase II and observational study. J. Neurol. Neurosurg. Psychiatry 2017, 88, 119–125. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vascellari, S.; Manzin, A. Parkinson’s Disease: A Prionopathy? Int. J. Mol. Sci. 2021, 22, 8022. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22158022
Vascellari S, Manzin A. Parkinson’s Disease: A Prionopathy? International Journal of Molecular Sciences. 2021; 22(15):8022. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22158022
Chicago/Turabian StyleVascellari, Sarah, and Aldo Manzin. 2021. "Parkinson’s Disease: A Prionopathy?" International Journal of Molecular Sciences 22, no. 15: 8022. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22158022